Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVCB87
|
|||
| Drug Name |
MK-5475
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Soluble guanylate cyclase (GCS) | Target Info | Stimulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05612035) A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health. | |||
| REF 2 | Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.